Research and development of metabolic and other chronic characteristic in-hospital preparations based on real-world data

Clinical observation of Tongfengqingli mixture on hyperuricemia complicated with lipid metabolism disorder and its effect on inflammatory factors

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200064637

Enrollment

Unknown

Registered

2022-10-13

Start date

2022-10-01

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperuricemia with abnormal lipid metabolism

Interventions

Experimental group:Medicinal herb

Control group:Western

Eligibility

Sex/Gender

All

Age

40 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. The age is between 40-75 years old; 2. Meet the diagnostic criteria of hyperuricemia and hyperlipidemia; 3. In line with the standard of TCM syndrome diagnosis; 4. No drugs affecting uric acid metabolism or excretion were used in the past 3 months.

Exclusion criteria

Exclusion criteria: 1. Patients with acute attack of gout; 2. Patients with secondary hyperuricemia were excluded, such as hematological diseases, malignant tumors, liver cirrhosis and renal failure; Certain endocrine disorders (e.g., hypercortisolism, hyperthyroidism, hyperparathyroidism, hypothyroidism); Caused by certain drugs (e.g. diuretics, aspirin, anti-tuberculous drugs, etc.); 3. Heart failure, unstable angina pectoris, severe arrhythmia, myocardial infarction in the past 12 months; Blood pressure SBP > 180mmHg or DBP > 100mmHg; A history of liver disease such as cirrhosis, hepatitis B or C (except carriers), or an AST or ALT 2.5 times higher than the upper limit of normal; Patients with a history of renal disease or clinically diagnosed renal insufficiency, and serum creatinine greater than 1.5mg/ dL (132.6umol/L); 4. People with mental disorders, drug or other substance abuse or alcoholism; Being treated with steroid hormones or being treated for malignancy; 5. Allergic constitution or allergic to the drugs used in this study; 6. Women who were pregnant or lactating, women of childbearing age who did not take effective contraceptive measures, or planned to become pregnant during the trial period, and urine HCG test results were positive.

Design outcomes

Primary

Measure	Time frame
Blood uric acid;Total cholesterol;Triglyceride;Low density lipoprotein;Hemorheology;High-density lipoprotein;	—

Secondary

Measure	Time frame
C-reactive protein;NALP3 (NAcht Leucine-rich repeat Protein 3);IL-1ß;Human urate transporter 1 (URAT1);Glucose transporter 9 (GLUT9);	—

Countries

China

Contacts

Public ContactDang Yuqi

Yinchuan Hospital of Traditional Chinese Medicine

360499735@qq.com+86 18909597819

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026